Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

BACKGROUND: Schizophrenia is often a persistent and costly illness that requires continued treatment with antipsychotics. Differences among antipsychotics on efficacy, safety, tolerability, adherence, and cost have cost-effectiveness implications for treating schizophrenia. This study compares the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Furiak, Nicolas M, Ascher-Svanum, Haya, Klein, Robert W, Smolen, Lee J, Lawson, Anthony H, Conley, Robert R, Culler, Steven D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679720/
https://www.ncbi.nlm.nih.gov/pubmed/19351408
http://dx.doi.org/10.1186/1478-7547-7-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679720/
https://www.ncbi.nlm.nih.gov/pubmed/19351408
http://dx.doi.org/10.1186/1478-7547-7-4

Ejemplares similares